Serum protein panel test can help identify cardiomyopathy risk in childhood cancer survivors

Findings from scientists at St. Jude Children's Research Hospital are showing promise for assessing cardiomyopathy risk in childhood cancer survivors. Heart disease is a well-established late effect for pediatric cancer survivors treated with anthracycline chemotherapy.

Read more: https://www.news-medical.net/news/20241203/Serum-protein-panel-test-can-help-identify-cardiomyopathy-risk-in-childhood-cancer-survivors.aspx